L’Assistance Publique – Hôpitaux de Paris and Bayer have announced the signing of a 3-year framework collaboration agreement. It aims to strengthen their partnership as well as the sharing of expertise in clinical research and artificial intelligence. The two entities thus wish to formalize their common intention to collaborate in research and development in order to facilitate the implementation of clinical studies within the AP-HP. This agreement will also allow the sharing of expertise in the framework of innovative projects such as the use of AI in areas of common interest.

As a renowned player in research infrastructure and for its teams, the PA-HP can rely on its Health Data Warehouse (HDS), a powerful tool that allows the implementation of projects using AI. This offers a considerable opportunity to develop new research methods and intelligent algorithms that offer a better understanding and management of diseases.

For its part, Bayer is currently conducting more than 45 clinical studies in France, more than half of which are in oncology, and is supporting 70 institutional studies, 62% of which are in partnership with AP-HP. Aware of the potential value associated with megadata and the interest of advanced analyses for the future of medicine and the interest of patients, Bayer is working on projects using AI to meet concrete medical needs. Such technologies could therefore help deliver the right treatment to the right patient at the right time, more efficiently and faster than today.

By signing this agreement, AP-HP and Bayer wish to enter into a partnership that promotes French excellence in medicine, clinical research and data science. Florence Favrel-Feuillade, Director of Clinical Research and Innovation at AP-HP said:

“This partnership with Bayer demonstrates the interest in the excellence of clinical researchers at AP-HP and their ability to combine their experience with the knowledge of other academic disciplines. We also see it as an opportunity to reveal the potential of data sources from healthcare (EDS_APHP) or research, thanks to clinical expertise coupled with tools using Artificial Intelligence. »

Dr. Moncef Boukerrou, Medical Director, Bayer France said:

“We are delighted with this agreement with AP-HP, which will strengthen France’s attractiveness for clinical research and artificial intelligence for the benefit of patients and practitioners. Bayer is committed to forging strategic partnerships with prestigious research organizations around the world. In France, this framework agreement enables the sharing of expertise in the context of innovative projects in areas of common interest, and is therefore perfectly in line with this approach. »

The terms and conditions of this collaboration are mainly aimed at :

• Improve the position of AP-HP and its professionals in Bayer’s development programs;
• Optimize the feasibility and contractualization process prior to the implementation of new clinical trials and any other type of research;
• To develop and share common activity and performance indicators relating to the clinical trials entrusted to us;
• To share know-how and organize team training when necessary;
• To set up collaborations using complementary skills and resources in the context of artificial intelligence projects enabling a better understanding and management of diseases.

Translated from Recherche clinique : L’AP-HP et Bayer signent un accord-cadre sur des projets innovants utilisant l’IA